Literature DB >> 33106290

Checking the Hippo in Sarcomatoid Renal Cell Carcinoma with Immunotherapy.

Joyce K Hwang1, Neeraj Agarwal2, James Brugarolas3, Tian Zhang4,5,6.   

Abstract

Subset analysis of patients with sarcomatoid renal cell carcinoma (sRCC) included in the CheckMate 214 trial of ipilimumab-nivolumab versus sunitinib showed improved outcomes in sRCC with ipilimumab-nivolumab. The use of checkpoint inhibitor-based regimens in sRCC, for which therapeutic options were once limited, is further supported by additional clinical trials.See related article by Tannir et al., p. 78. ©2020 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33106290      PMCID： PMC7785667          DOI： 10.1158/1078-0432.CCR-20-3506

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   13.801


  8 in total

1.  Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape.

Authors:  Zixing Wang; Tae Beom Kim; Bo Peng; Jose Karam; Chad Creighton; Aron Joon; Fumi Kawakami; Patricia Trevisan; Eric Jonasch; Chi-Wan Chow; Jaime Rodriguez Canales; Pheroze Tamboli; Nizar Tannir; Christopher Wood; Federico Monzon; Keith Baggerly; Marileila Varella-Garcia; Bogdan Czerniak; Ignacio Wistuba; Gordon Mills; Kenna Shaw; Ken Chen; Kanishka Sircar
Journal:  Clin Cancer Res       Date:  2017-07-14       Impact factor: 12.531

2.  An Empirical Approach Leveraging Tumorgrafts to Dissect the Tumor Microenvironment in Renal Cell Carcinoma Identifies Missing Link to Prognostic Inflammatory Factors.

Authors:  Rong Lu; Payal Kapur; Bijay S Jaiswal; Tao Wang; Raquibul Hannan; Ze Zhang; Ivan Pedrosa; Jason J Luke; He Zhang; Leonard D Goldstein; Qurratulain Yousuf; Yi-Feng Gu; Tiffani McKenzie; Allison Joyce; Min S Kim; Xinlei Wang; Danni Luo; Oreoluwa Onabolu; Christina Stevens; Zhiqun Xie; Mingyi Chen; Alexander Filatenkov; Jose Torrealba; Xin Luo; Wenbin Guo; Jingxuan He; Eric Stawiski; Zora Modrusan; Steffen Durinck; Somasekar Seshagiri; James Brugarolas
Journal:  Cancer Discov       Date:  2018-06-08       Impact factor: 39.397

3.  Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma.

Authors:  Mark Bi; Siming Zhao; Jonathan W Said; Maria J Merino; Adebowale J Adeniran; Zuoquan Xie; Cayce B Nawaf; Jaehyuk Choi; Arie S Belldegrun; Allan J Pantuck; Harriet M Kluger; Kaya Bilgüvar; Richard P Lifton; Brian Shuch
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-10       Impact factor: 11.205

4.  Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma.

Authors:  Nizar M Tannir; Sabina Signoretti; Toni K Choueiri; David F McDermott; Robert J Motzer; Abdallah Flaifel; Jean-Christophe Pignon; Miriam Ficial; Osvaldo Arén Frontera; Saby George; Thomas Powles; Frede Donskov; Michael R Harrison; Philippe Barthélémy; Scott S Tykodi; Judit Kocsis; Alain Ravaud; Jeronimo R Rodriguez-Cid; Sumanta K Pal; Andre M Murad; Yuko Ishii; Shruti Shally Saggi; M Brent McHenry; Brian I Rini
Journal:  Clin Cancer Res       Date:  2020-09-01       Impact factor: 12.531

5.  Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial.

Authors:  Robert J Motzer; Bernard Escudier; David F McDermott; Osvaldo Arén Frontera; Bohuslav Melichar; Thomas Powles; Frede Donskov; Elizabeth R Plimack; Philippe Barthélémy; Hans J Hammers; Saby George; Viktor Grünwald; Camillo Porta; Victoria Neiman; Alain Ravaud; Toni K Choueiri; Brian I Rini; Pamela Salman; Christian K Kollmannsberger; Scott S Tykodi; Marc-Oliver Grimm; Howard Gurney; Raya Leibowitz-Amit; Poul F Geertsen; Asim Amin; Yoshihiko Tomita; M Brent McHenry; Shruti Shally Saggi; Nizar M Tannir
Journal:  J Immunother Cancer       Date:  2020-07       Impact factor: 13.751

6.  Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial.

Authors:  Brian I Rini; Robert J Motzer; Thomas Powles; David F McDermott; Bernard Escudier; Frede Donskov; Robert Hawkins; Sergio Bracarda; Jens Bedke; Ugo De Giorgi; Camillo Porta; Alain Ravaud; Francis Parnis; Enrique Grande; Wei Zhang; Mahrukh Huseni; Susheela Carroll; Roxana Sufan; Christina Schiff; Michael B Atkins
Journal:  Eur Urol       Date:  2020-07-09       Impact factor: 24.267

Review 7.  Sarcomatoid Dedifferentiation in Renal Cell Carcinoma: From Novel Molecular Insights to New Clinical Opportunities.

Authors:  Véronique Debien; Jonathan Thouvenin; Véronique Lindner; Philippe Barthélémy; Hervé Lang; Ronan Flippot; Gabriel G Malouf
Journal:  Cancers (Basel)       Date:  2019-12-31       Impact factor: 6.639

8.  Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers.

Authors:  Gabriel G Malouf; Ronan Flippot; Yiyu Dong; Nizar M Tannir; Abraham A Hakimi; Renzo G Dinatale; Ying-Bei Chen; Xiaoping Su; Eva Compérat; Morgan Rouprêt; Roy Mano; Kyle A Blum; Hui Yao; Roger Mouawad; Jean-Philippe Spano; David Khayat; Jose A Karam; Thai H Ho; Satish K Tickoo; Paul Russo; James J Hsieh
Journal:  Sci Rep       Date:  2020-01-20       Impact factor: 4.379
  8 in total
  1 in total

Review 1.  The Role of Cytoreductive Nephrectomy in Renal Cell Carcinoma with Sarcomatoid Histology: A Case Series and Review of the Literature.

Authors:  Hana Studentova; Nikol Rusarova; Andrea Ondruskova; Anezka Zemankova; Vladimir Student; Daniela Skanderova; Bohuslav Melichar
Journal:  Curr Oncol       Date:  2022-08-03       Impact factor: 3.109
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.